<DOC>
	<DOCNO>NCT00847886</DOCNO>
	<brief_summary>The purpose study evaluate effect LX3305 methotrexate ( MTX ) pharmacokinetics evaluate safety tolerability LX3305 give 14 day subject stable rheumatoid arthritis receive stable dos MTX .</brief_summary>
	<brief_title>Study LX3305 Methotrexate Subjects With Stable Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Males female â‰¥ 18 year old Must willing practice 2 adequate method contraception duration study Rheumatoid arthritis present least 3 month ; functional class I , II , III define ACR criterion Treatment methotrexate ( 7.5 25 mg per week ) least last 3 month , currently receive stable dose methotrexate least one month prior start study Ability provide write informed consent Women pregnant nursing History current inflammatory arthritis History opportunistic infection History recurrent infection current infection 2 week prior start study Presence significant , uncontrolled medical problem Treatment diseasemodifying antirheumatoid drug methotrexate within 4 week prior start study Use chondroitin sulfate , glucosamine sulfate , minocycline , matrix metalloproteinase inhibitor , H2 blocker , proton pump inhibitor , misoprostol within 4 week prior study start Receipt live vaccine within 8 week prior study start Rheumatoid arthritis , functional class IV define ACR criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>